![Charles Ryan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Charles Ryan
President chez
QUINCE THERAPEUTICS, INC.
Fortune : 14 950 $ au 31/05/2026
Profil
Charles S.
Ryan is Chief Executive Officer at Quince Therapeutics SpA since 2023.
Holds director positions at GlycoMira LLC, Polaryx Therapeutics, Inc. starting 2026, and is a member of the New York State Bar Association.
Serves as President of Quince Therapeutics, Inc. since 2023 and trustee at The College of Wooster.
Formerly served as President, Chief Executive Officer & Director at Orthobond Corp.
from 2016 to 2018.
Chief Executive Officer & Director at Neurotrope, Inc. from 2018 to 2020.
Chief Executive Officer & Director at TAO Synergies, Inc. from 2018 to 2020.
Chief Executive Officer & Director at Petros Pharmaceuticals, Inc. Chairman, President & Chief Executive Officer at Travecta Therapeutics Pte Ltd. from 2017 to 2022.
Chairman-Development Council at Stony Brook University Medical Center.
Independent Director at BNB Plus Corp.
from 2011 to 2019.
Director at New York Biotechnology Association, Inc. Independent Director at BioRestorative Therapies, Inc. from 2015 to 2020.
Director at ABS Materials, Inc. and GlycoMira Therapeutics, Inc. Chief Intellectual Property Counsel & Senior VP at Forest Laboratories, Inc. from 2003 to 2014.
Vice President & General Counsel at Engelhard Long Island, Inc. from 1998 to 2002.
Trustee at Western New England University.
Chief Operating Officer at LAB21, Inc. from 2002 to 2003.
Vice President & General Counsel at Cold Spring Harbor Laboratory, Inc. from 2015 to 2016.
Education includes a doctorate from Stony Brook University in 1990, a graduate degree from Western New England University School of Law in 1993, and an undergraduate degree from The College of Wooster in 1986.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/04/2026 | 13 000 ( 0,08 % ) | 14 950 $ | 31/05/2026 |
Postes actifs de Charles Ryan
| Sociétés | Poste | Début |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | President | 01/09/2023 |
| POLARYX THERAPEUTICS, INC. | Directeur/Membre du Conseil | 29/01/2026 |
New York State Bar Association
 New York State Bar Association Miscellaneous Commercial ServicesCommercial Services Operates as a bar association | Corporate Officer/Principal | - |
GlycoMira LLC
 GlycoMira LLC Medical/Nursing ServicesHealth Services GlycoMira LLC is a clinical-stage biotechnology company developing mechanism-based oncology therapeutics focused on solid tumors and therapy-resistant cancers with inflammatory origins. The company is based in Salt Lake City, UT. The company's lead drug candidate, GM-1111, is an innate immune system modulator derived from naturally occurring polysaccharides that targets multiple molecular factors in the tumor microenvironment to inhibit innate immune receptor activation, reduce inflammatory signaling, tumor growth, treatment resistance, and cancer stem cell activity. Preclinical studies show GM-1111’s potential to enhance radiation therapy efficacy in head and neck cancers and mitigate radiation-induced oral mucositis. | Directeur/Membre du Conseil | - |
The College of Wooster
 The College of Wooster Other Consumer ServicesConsumer Services Functions as a College/University | Directeur/Membre du Conseil | - |
EryDel SpA
 EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Directeur Général | 01/09/2023 |
Anciens postes connus de Charles Ryan
| Sociétés | Poste | Fin |
|---|---|---|
Travecta Therapeutics Pte Ltd.
 Travecta Therapeutics Pte Ltd. Packaged SoftwareTechnology Services Develops a novel chemistry platform for delivery of therapies to the brain | Directeur Général | 01/10/2022 |
| SYNAPTOGENIX, INC. | Directeur Général | 01/12/2020 |
| NEUROTROPE, INC. | Directeur Général | 01/12/2020 |
| ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░ ░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Charles Ryan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
54
Relations au 1er degré
24
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 24 |
|---|---|
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells drug products | Health Technology |
Applied DNA Sciences, Inc.
 Applied DNA Sciences, Inc. BiotechnologyHealth Technology Manufactures DNA for use in the nucleic acid-based in vitro medical diagnostics and preclinical nucleic acid-based drug development and manufacturing markets | Health Technology |
Orthobond Corp.
 Orthobond Corp. Miscellaneous Commercial ServicesCommercial Services Operates as an antimicrobial technology company that develops proprietary related nanosurfaces | Commercial Services |
GlycoMira LLC
GlycoMira LLC Medical/Nursing ServicesHealth Services GlycoMira LLC is a clinical-stage biotechnology company developing mechanism-based oncology therapeutics focused on solid tumors and therapy-resistant cancers with inflammatory origins. The company is based in Salt Lake City, UT. The company's lead drug candidate, GM-1111, is an innate immune system modulator derived from naturally occurring polysaccharides that targets multiple molecular factors in the tumor microenvironment to inhibit innate immune receptor activation, reduce inflammatory signaling, tumor growth, treatment resistance, and cancer stem cell activity. Preclinical studies show GM-1111’s potential to enhance radiation therapy efficacy in head and neck cancers and mitigate radiation-induced oral mucositis. | Health Services |
Neurotrope, Inc.
 Neurotrope, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for neurodegenerative diseases | Health Technology |
Engelhard Long Island, Inc.
 Engelhard Long Island, Inc. Miscellaneous Commercial ServicesCommercial Services Provides consulting and analytical services | Commercial Services |
Stony Brook University
 Stony Brook University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Western New England University
 Western New England University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LAB21, Inc.
 LAB21, Inc. Medical/Nursing ServicesHealth Services Provides laboratory testing services and distributes diagnostic products | Health Services |
New York State Bar Association
New York State Bar Association Miscellaneous Commercial ServicesCommercial Services Operates as a bar association | Commercial Services |
Cold Spring Harbor Laboratory, Inc.
 Cold Spring Harbor Laboratory, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research services | Commercial Services |
New York Biotechnology Association, Inc.
 New York Biotechnology Association, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as an association that promotes the biotechnology industry | Commercial Services |
EryDel SpA
EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Health Technology |
Stony Brook University Medical Center
 Stony Brook University Medical Center Hospital/Nursing ManagementHealth Services Operates a hospital | Health Services |
BioRestorative Therapies, Inc.
 BioRestorative Therapies, Inc. Medical SpecialtiesHealth Technology Develops stem cell therapies to address unmet needs in patients with highly prevalent conditions | Health Technology |
ABS Materials, Inc.
 ABS Materials, Inc. Home FurnishingsConsumer Durables Develops reactive glass products and nanosands | Consumer Durables |
Synaptogenix, Inc.
 Synaptogenix, Inc. Packaged SoftwareTechnology Services Develops decentralized blockchain network that focuses on convergence between cryptocurrency and artificial intelligence | Technology Services |
Western New England University School of Law
 Western New England University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Quince Therapeutics, Inc.
 Quince Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops drugs for the treatment of central nervous system disorders and Alzheimer’s diseases | Health Technology |
Travecta Therapeutics Pte Ltd.
Travecta Therapeutics Pte Ltd. Packaged SoftwareTechnology Services Develops a novel chemistry platform for delivery of therapies to the brain | Technology Services |
GlycoMira Therapeutics, Inc.
 GlycoMira Therapeutics, Inc. BiotechnologyHealth Technology Develops glycosaminoglycan-based therapeutics | Health Technology |
Petros Pharmaceuticals, Inc.
 Petros Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers and distributes pharmaceutical products | Health Technology |
Polaryx Therapeutics, Inc.
 Polaryx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that engages in discovery, development and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders | Commercial Services |
The College of Wooster
The College of Wooster Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
